Affy to Restate Financials Back to 1997 After Uncovering 'Certain Lapses' in Option Grants | GenomeWeb
NEW YORK (GenomeWeb News) – Affymetrix late yesterday said it will restate its financial results as far back as 1997 after an internal review into its stock-option granting practices turned up “certain documentation lapses.”
 
The company said the restatements will increase its previously reported net losses from 1997 to 2002, reduce its previously reported net income for 2003, and increase its previously reported net income in 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.